OBSERVATIONS ON THE EFFECT OF MAGNESIUM ON BLOOD COAGULATION

BY

R. G. HUNTSMAN, B. A. L. HURN, AND H. LEHMANN

From Lewisham Group Laboratory, Lewisham Hospital, and the Department of Pathology, St. Bartholomew's Hospital, London

(RECEIVED FOR PUBLICATION OCTOBER 27, 1959)

Previous observations on the effect of oral magnesium and peptone on thrombin generation time are examined. The smallest amounts of magnesium and peptone regularly producing a significant shift demonstrable after one hour are 0.25 g. magnesium and 15 g. peptone.

The oral effect can be reproduced by the intravenous injection of magnesium. The minimum amount required is 50 mg. The effect is transient, and after 30 minutes can no longer be demonstrated.

Amounts of magnesium of the same order as those acting on intravenous injection can produce a shift of thrombin generation time in vitro. This action of magnesium in vitro can be antagonized by the addition of calcium.

Small amounts of magnesium added to fresh unclotted human plasma prolong the clotting time considerably. This action was shown to be due to an antagonism between Mg++ and Ca++, both competing for combination with clotting factors (Greville and Lehmann, 1944). Such ion antagonism had been demonstrated in muscle and in nerve end-plates where the breakdown of adenosine triphosphate is activated by Ca++ in muscle and by Mg++ in end-plates (Greville and Lehmann, 1943). The amount of magnesium required to demonstrate this effect in vitro was about 10 times the normal plasma level, and considerably greater than that could be practically achieved in vivo. Attempts to test the action of magnesium in vivo were, however, made, notably in Germany, where, during and shortly after the 1939–45 war, magnesium sulphate was widely used as a muscle relaxant. It was noted that the blood of some patients examined post mortem after such treatment had remained unclotted. Schnitzler (1957) has summarized these experiences in his report on the use of 200 mg. of magnesium given three times daily, post partum, to prevent thrombosis. We have not been able to confirm his results, which indicated a highly significant prolongation of the whole blood clotting-time after a single dose of 300 mg. of magnesium. Malkiel-Shapiro, Bersohn, and Terner (1956) claimed that they improved the clinical state of patients with coronary disease when they administered magnesium parenterally. This they related to an effect of the magnesium on the coagulation mechanism. Brown, McGandy, Gillie, and Doyle (1958) were unable to find such a relation between magnesium and lipids in health or in disease. Anstall, Huntsman, Lehmann, Hayward, and Weitzman (1959) described the effect of the oral administration of 1 g. magnesium on the clotting processes. Peptone had to be given with the magnesium to increase its absorption. This was thought to be due to the effect of amino-acids on the solubility of sparingly soluble salts of divalent cations, as demonstrated by Lehmann and Pollak (1942). Glutamic acid was also effective. To demonstrate the effect it was necessary to use the whole blood thrombin generation test (Macfarlane and Biggs, 1953), rather than the clotting time (Lee and White). A delay in thrombin generation of at least four minutes was obtained in successful experiments one hour after the administration of 1 g. Mg++ and 50 g. peptone. Both had to be given together, and neither could produce this effect alone. It was not always possible to demonstrate a rise in the serum magnesium concentration in otherwise successful tests.

The present paper describes attempts to elucidate the following aspects of this effect:

(1) The minimum amount of orally administered magnesium and peptone required to produce a shift in thrombin generation time;
(2) the relation between the effect obtained by orally administered magnesium and that obtained by intravenous injection;

(3) the relation between the effect obtained by intravenous injection and that exerted by the addition of magnesium to fresh blood in vitro.

Experimental Procedure

Macfarlane and Biggs's thrombin generation test (1953) was performed as previously described (Anstall et al., 1959). For the work in vitro, 5 ml of blood was drawn into a siliconed syringe already containing either 0.1 ml of water or the salts under investigation dissolved in a constant volume of 0.1 ml of water.

Results

Varying the Quantity of Oral Magnesium and Peptone.—The same effect obtained with 1 g of magnesium and 50 g of peptone could also be produced with 0.25 g of magnesium and 15 g of peptone, but, whereas with the first amounts the shift in thrombin generation could be demonstrated for five to six hours, with the second amounts it was present after one hour, but could no longer be found after two hours. Lowering the magnesium dose below 0.25 g yielded equivocal results, regardless of how much peptone was given; and lowering the peptone below 15 g yielded, with some individual constancy, negative results in some, and equivocal or positive results in other subjects. Table I shows results of a typical series of experiments performed on one individual at intervals of four to seven days.

### Table I

**EFFECT OF ORAL MAGNESIUM AND PEPTONE ON THROMBIN GENERATION TIME**

<table>
<thead>
<tr>
<th>Magnesium Citrate (g, Mg)</th>
<th>Peptone (g)</th>
<th>Before Dose</th>
<th>One Hour after Dose</th>
<th>Shift</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>50</td>
<td>10</td>
<td>154</td>
<td>54</td>
</tr>
<tr>
<td>0.5</td>
<td>30</td>
<td>12</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>0.25</td>
<td>15</td>
<td>12</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>0.25</td>
<td>7.5</td>
<td>13</td>
<td>15</td>
<td>2</td>
</tr>
</tbody>
</table>

Injection of Magnesium.—Blood was withdrawn first to determine the basal time of thrombin generation. Afterwards, magnesium sulphate or magnesium chloride was injected intravenously in a volume of 1 to 2 ml. Blood was withdrawn five minutes later to allow for a thorough distribution of the magnesium. A shift in thrombin generation of four to five minutes' duration was found regularly after the injection of 50 mg. Mg++. Some effect could be found 15 minutes after the injection of 50 mg., but it had vanished after 30 minutes. No significant shift was obtained after the injection of 25 mg of the ion.

The transient nature of the change after the intravenous injection is in marked contrast to the action of the orally administered magnesium and peptone (1 g and 50 g respectively), lasting for six hours. It is evident that, once absorbed, the effect of magnesium on clotting is rapidly neutralized, and it would, therefore, appear that the slow absorption after taking magnesium by mouth may be therapeutically advantageous. Judging from the rapidity with which the effect of intravenously administered magnesium diminishes, it might be assumed that even after only five minutes a decay in activity may already have occurred. Thus, it is possible that were this decay not so pronounced (or, as in oral dosage, if the magnesium slowly and continuously enters the blood stream), a much smaller quantity might have a significant effect. This could account for the frequent failure to demonstrate a rise in serum magnesium in otherwise successful experiments.

**Experiments in Vitro.**—Table II shows two typical experiments demonstrating the effect of small amounts of magnesium added to fresh-drawn blood. The amount of magnesium added in vitro was of the same order as those which
had produced a shift in thrombin generation in vivo. Equivalent amounts of potassium chloride and potassium sulphate had no effect. The fact that magnesium at such concentrations caused a shift in thrombin generation in vitro suggests that the action in vivo is directly on the blood, rather than intermittently on some other organ or system in the body.

Table II also illustrates another aspect of the magnesium effect. We had previously suggested (Anstall et al., 1959) that Mg++ acted by competing with Ca++ when it was added to a clotting system in which Ca++ was in its optimal concentration. Large amounts of Ca++ added to blood are, of course, known to inhibit clotting. Furthermore, Mg++ will antagonize Ca++ when this ion is at its optimal concentration. If Ca++ is below its optimal concentration, Mg++ may actually activate the process which is catalysed by Ca++, since on taking its place in that process it will not replace available Ca++ but complement the insufficient amount of catalyst available. These relationships have been set out in detail by Greville and Lehmann (1943, 1944), whose work took its origin from the contradictory results reported on the effect of Mg++ on the adenosine triphosphate splitting activity of myosin, some workers having described an activation, others an inhibition. Since then Born (1956) has reported that platelets have a high adenosine triphosphate content which falls rapidly on clotting, and Bettex-Galland and Lüscher (1959) have described an actomyosin-like protein prepared from platelets.

It was found that 0.5 mg. of Ca++ added to 5 ml. of blood had no significant effect on thrombin generation. This quantity was, therefore, considered suitable for demonstrating any possible antagonism of Ca++ on the effect of Mg++ (see Table II). It will be seen in Table II that 0.5 mg. of Ca++ by itself did not influence the thrombin generation time but that it considerably shortened the shift produced by 0.15 mg. or 0.3 mg. of Mg++. These results link the present work with earlier observations of Greville and Lehmann (1944), who, however, used larger amounts of both ions and tested the whole plasma clotting time.

References
Born, G. V. R. (1956). J. Physiol. (Lond.), 133, 61P.
OBSERVATIONS ON THE EFFECT OF MAGNESIUM ON BLOOD COAGULATION

R. G. Huntsman, B. A. L. Hurn and H. Lehmann

doi: 10.1136/jcp.13.2.99

Updated information and services can be found at:
http://jcp.bmj.com/content/13/2/99

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/